[의학신문·일간보사=안치영 기자] The Korea Biotechnology Association (Chairman Hanseung Koh) will hold an ‘Open Innovation Challenge’ with global pharmaceutical company Novartis on the 22nd.
This event will be held as part of the ‘Global Mingle’ overseas expansion program planned by the association to support domestic bio companies’ overseas expansion and establishment of cooperative networks.
The ‘Open Innovation Challenge’ conducted with Novartis this time recruited domestic bio companies who wanted to participate from the 14th of last month to the 7th of this month. Accordingly, as the second follow-up meeting, a meeting with Novartis headquarters will be held.
The fields of cooperation that Novartis hopes for in the 1st Open Innovation Challenge on the 22nd are △Atrial fibrillation treatment technique △Immunotolerance/immune rebalancing treatment for auto-immune diseases) △Oral small molecule on IL-17TYK2 (IL-17TYK2) △Engineered Treg cell therapies, and companies with the technology were recruited.
Through this first 1:1 meeting, it is expected that Novartis will be able to review the R&D capabilities of participating bio companies, provide innovative solutions, and the possibility of global connection, and explore possibilities that can lead to actual collaboration.
Hwang Joo-ri, head of the exchange and cooperation team at the Korea Biotechnology Association, said, “Through the open innovation challenge with global pharmaceutical companies, domestic bio start-ups will continue to provide a platform for open collaboration in more diverse categories, such as joint research, as well as technology export.”
In addition to this time, the ‘Open Innovation Challenge’ conducted by the Korea Bio Association with Novartis is scheduled to be held regularly within the year with bio companies in the field of cooperation to discover new drug candidates that Novartis is interested in. ) will be recruiting partners.
